Hemodynamics and pharmacokinetics of tezosentan, a dual endothelin receptor antagonist, in patients with cirrhosis-Reference-Cited by-同舟云学术

Hemodynamics and pharmacokinetics of tezosentan, a dual endothelin receptor antagonist, in patients with cirrhosis

Published:2011-11-20 Issue:5 Volume:68 Page:533-541
ISSN:0031-6970
Container-title:European Journal of Clinical Pharmacology
language:en
Short-container-title:Eur J Clin Pharmacol

Author:

Lebrec Didier,Bosch Jaime,Jalan Rajiv,Dudley Francis J.,Jessic Rada,Moreau Richard,Garcia-Pagan Juan Carlos,Mookerjee Rajeshwar P.,Chiossi Eleonora,Van Giersbergen Paul L. M.,Kusic-Pajic Andjela,Dingemanse Jasper

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00228-011-1157-6.pdf

Reference32 articles.

1. Iwakiri Y, Grisham M, Shah V (2008) Vascular biology and pathobiology of the liver: report of a single-topic symposium. Hepatology 47:1754–1763

2. Rockey D (1997) The cellular pathogenesis of portal hypertension: stellate cell contractility, endothelin, and nitric oxide. Hepatology 25:2–5

3. Yanagisawa M, Kurihara H, Kimura Y, Tomobe Y, Kobayashi M, Mitsui Y et al (1988) A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332:411–415

4. Moore K, Wendon J, Frazer M, Karami J, Williams R, Badr K et al (1992) Plasma endothelin immunoreactivity in liver disease and the hepatorenal syndrome. N Engl J Med 327:1774–1778

5. Uchihara M, Izumi N, Sato C, Marumo F (1992) Clinical significance of elevated plasma endothelin concentration in patients with cirrhosis. Hepatology 16:95–99

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Microarray analysis demonstrates up-regulation of the endothelin-1 gene with compensatory down-regulation of the ETA receptor gene in human portal vein;Bioscience Reports;2024-07

2. Repurposing of the Drug Tezosentan for Cancer Therapy;Current Issues in Molecular Biology;2023-06-11

3. Emerging Therapeutic Targets for Portal Hypertension;Current Hepatology Reports;2023-02-11

4. Investigational drugs in early clinical development for portal hypertension;Expert Opinion on Investigational Drugs;2022-07-05

5. Endothelins and liver cirrhosis;Portal Hypertension & Cirrhosis;2022-06